Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management.

Holt, Richard I.G. and Peveler, Robet C. (2010) Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clinical Endocrinology (doi:10.1111/j.1365-2265.2010.03814.x). (PMID:20455888).


Full text not available from this repository.


Hyperprolactinaemia is a common side effect in people receiving antipsychotics. The propensity to cause hyperprolactinaemia differs markedly between antipsychotics as a result of differential dopamine D2 receptor binding affinity and ability to cross the blood-brain barrier. Sexual dysfunction is common and under-recognised in people with severe mental illness and is in part caused by hyperprolactinaemia. There are a number of long term consequences of hyperprolactinaemia, including osteoporosis.

Regular monitoring before and during treatment will help identify those developing antipsychotic-induced hyperprolactinaemia. The treatment includes dose reduction and change in antipsychotic. Where this is not possible because of the risk of relapse of the mental illness, sex steroid replacement may be helpful in improving symptoms secondary to hypogonadism and reducing the risk of osteoporosis. Tertiary prevention of complications should also be considered.

Item Type: Article
Digital Object Identifier (DOI): doi:10.1111/j.1365-2265.2010.03814.x
Keywords: severe mental illness, antipsychotic, hyperprolactinaemia, sexual dysfunction, osteoporosis, breast cancer, monitoring, management

ePrint ID: 166061
Date :
Date Event
23 April 2010e-pub ahead of print
Date Deposited: 21 Oct 2010 13:42
Last Modified: 18 Apr 2017 03:38
Further Information:Google Scholar

Actions (login required)

View Item View Item